The global glycomics market size was estimated to be US$ 1.21 billion in 2021 and is expected to grow at a CAGR of 12.5% between 2023 to 2032.
The complete study of the structure and the function of glycans in a given cell or an organism is known as glycomics. Glycans, also called polysaccharides, are carbohydrate-based polymers made by all living organisms. Glycans are essential biomolecules serving structure, energy storage and system regulatory purposes. There are plant, animal, and microbial glycans according to their biological sources.
Some common applications of glycomics are drug discovery, immunology and diagnostics. Glycomics uses various techniques to quantify or define the glycome of a tissue, cell or organism such as high-performance liquid chromatography (HPLC) and matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF-MS).
Mutations in the activity of enzymes involved in glycan biosynthesis results in modification of the final glycan structure. Therefore, apart from observing the genome of the cells, glycans can be analyzed to track environmentally induced changes. Such studies are used in disease diagnosis and drug discovery. This is one of the main reasons propelling market growth.
Several new glycoside inhibitors are now commercialized that alter N-linked glycans of cancer cells and viruses. Such enzymes are used clinically to direct antiviral, antibacterial and anti-cancer activities in diseases caused by deficiencies such as Tay-Sachs disease and Gaucher disease, and most importantly, diabetes.
Various studies have reported that epigenetic regulation of glycans in cancer cells results in formation of new glycan structures. These new glycans are formed due to the pathways used by cancer cells to evade immune response in a host. Scientists have designed genetic engineered cell models to understand functions of specific glycan cancer epitopes. These factors are therefore anticipated to propel market growth during the forecast period.
The global pandemic of COVID-19 has given biopharmaceutical and pharmaceutical companies numerous opportunities to increase their research and development budgets in order to develop novel molecules, compounds and vaccines based on glycan data analysis for containing the spread and treatment of seriously ill patients. As the number of clinical trials increase so does the need for biopharmaceutical organizations to commercialize new glycomics based enzymes.
High costs incurred due to tools and techniques used to perform glycan data analysis, are expected to obstruct the market growth. Lack of skilled professionals to perform glycan data analysis procedures such as MALDI-TOF-MS, HPLC is likely to restrain the global glycomics market.
Glycomics Market Share Analysis, by Geography (2022)
The major players covered in the glycomics market report are Merck & Co Inc, Shimadzu Corporation, Bruker, ProZyme, WATERS, Thermo Fisher Scientific, Agilent Technologies, New England Biolabs, Asparia Glycomics, Vector Laboratories, Beth Israel Deaconess Medical Center, glyconet Berlin Brandenburg eV, University of Georgia, GlySign, Canadian Glycomics Network, GlycoDisplay, RayBiotech, Glycodiag, Laboratorios farmaceuticos rovi sa, Glyco Expression Technologies Inc and others.
By Product
By Application
By End-user
By Geography
The global glycomics market is estimated to expand at a CAGR of 12.5% through 2032.
The complete study of the structure and the function of glycans in a given cell or an organism is known as glycomics.
Scientists have designed genetic engineered cell models to understand functions of specific glycan cancer epitopes. These factors are therefore anticipated to propel glycomics market growth during the forecast period.
The glycomics market was valued at US$ 1.21 billion in 2021.
Glycomics are largely used in the Diagnostics, Drug Discovery & Development, Oncology, Immunology and Other Applications.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved